PURPOSE: To estimate the α/β ratio for which the dose-dependent lung perfusion reductions for stereotactic body radiation therapy (SBRT) and conventionally fractionated radiation therapy (CFRT) are biologically equivalent. METHODS AND MATERIALS: The relations between local dose and perfusion reduction 4 months after treatment in lung cancer patients treated with SBRT and CFRT were scaled according to the linear-quadratic model using α/β ratios from 0 Gy to ∞ Gy. To test for which α/β ratio both treatments have equal biological effect, a 5-parameter logistic model was optimized for both dose-effect relationships simultaneously. Beside the α/β ratio, the other 4 parameters were d50, the steepness parameter k, and 2 parameters (MSBRT and MCFRT) representing the maximal perfusion reduction at high doses for SBRT and CFRT, respectively. RESULTS: The optimal fitted model resulted in an α/β ratio of 1.3 Gy (0.5-2.1 Gy), MSBRT=42.6% (40.4%-44.9%), MCFRT=66.9% (61.6%-72.1%), d50=35.4 Gy (31.5-9.2 Gy), and k=2.0 (1.7-2.3). CONCLUSIONS: An equal reduction of lung perfusion in lung cancer was observed in SBRT and CFRT if local doses were converted by the linear-quadratic model with an α/β ratio equal to 1.3 Gy (0.5-2.1 Gy).
PURPOSE: To estimate the α/β ratio for which the dose-dependent lung perfusion reductions for stereotactic body radiation therapy (SBRT) and conventionally fractionated radiation therapy (CFRT) are biologically equivalent. METHODS AND MATERIALS: The relations between local dose and perfusion reduction 4 months after treatment in lung cancerpatients treated with SBRT and CFRT were scaled according to the linear-quadratic model using α/β ratios from 0 Gy to ∞ Gy. To test for which α/β ratio both treatments have equal biological effect, a 5-parameter logistic model was optimized for both dose-effect relationships simultaneously. Beside the α/β ratio, the other 4 parameters were d50, the steepness parameter k, and 2 parameters (MSBRT and MCFRT) representing the maximal perfusion reduction at high doses for SBRT and CFRT, respectively. RESULTS: The optimal fitted model resulted in an α/β ratio of 1.3 Gy (0.5-2.1 Gy), MSBRT=42.6% (40.4%-44.9%), MCFRT=66.9% (61.6%-72.1%), d50=35.4 Gy (31.5-9.2 Gy), and k=2.0 (1.7-2.3). CONCLUSIONS: An equal reduction of lung perfusion in lung cancer was observed in SBRT and CFRT if local doses were converted by the linear-quadratic model with an α/β ratio equal to 1.3 Gy (0.5-2.1 Gy).
Authors: Abraham J Wu; Eric Williams; Ankit Modh; Amanda Foster; Ellen Yorke; Andreas Rimner; Andrew Jackson Journal: Radiother Oncol Date: 2014-07-23 Impact factor: 6.280
Authors: J J Gordon; K Snyder; H Zhong; K Barton; Z Sun; I J Chetty; M Matuszak; R K Ten Haken Journal: Phys Med Biol Date: 2015-08-21 Impact factor: 3.609
Authors: D Schlesinger; M Lee; G Ter Haar; B Sela; M Eames; J Snell; N Kassell; J Sheehan; J M Larner; J-F Aubry Journal: Int J Hyperthermia Date: 2017-01-31 Impact factor: 3.914
Authors: Yanyan Jiang; Jennifer Martin; Maryam Alkadhimi; Kay Shigemori; Paul Kinchesh; Stuart Gilchrist; Veerle Kersemans; Sean Smart; James M Thompson; Mark A Hill; Mark J O'Connor; Barry R Davies; Anderson J Ryan Journal: Br J Cancer Date: 2021-03-19 Impact factor: 7.640
Authors: Antonia E Wuschner; Eric M Wallat; Mattison J Flakus; Dhanansayan Shanmuganayagam; Jennifer Meudt; Gary E Christensen; Joseph M Reinhardt; Jessica R Miller; Michael J Lawless; Andrew M Baschnagel; John E Bayouth Journal: Sci Rep Date: 2021-06-23 Impact factor: 4.996
Authors: X Liang; J Penagaricano; D Zheng; S Morrill; X Zhang; P Corry; R J Griffin; E Y Han; M Hardee; V Ratanatharathom Journal: Radiat Oncol Date: 2016-01-22 Impact factor: 3.481